NasdaqGS:NVAXBiotechs
Assessing Novavax (NVAX) Valuation As Shah Capital Challenges Leadership And Sanofi Partnership
Activist pressure puts Novavax (NVAX) leadership under scrutiny
Shah Capital Management has challenged Novavax (NVAX) leadership in a detailed Elevating Novavax Presentation, criticizing marketing since 2023, the Sanofi partnership, capital market decisions, and executive conduct toward shareholder value.
See our latest analysis for Novavax.
The activist presentation lands after a period where momentum in Novavax’s share price has been mixed, with a 1-month share price return of 8.99% and a...